Puma Biotechnology Inc (PBYI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $379.47M
Last updated: Nov 17, 2026 at 4:41 PM ET
Puma Biotechnology Inc (PBYI) Statistics
Puma Biotechnology (PBYI) has a market cap of $379.47M and an enterprise value of $337.92M. Its trailing P/E of 14.6x is above its 5-year median of 9.9x. It holds $41.55M more cash than debt, 10.95% of its market cap.
Total Valuation
Enterprise value is 10.95% below the market cap, as cash exceeds debt.
| Market Cap | $379.47M |
|---|---|
| Enterprise Value | $337.92M |
| Latest price (Nov 17, 2026) | $7.14 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.6x and 2.5x. Its year-end P/E ranged from 3.9x to 21.1x from 2022 to 2025.
| P/E Ratio | 14.6x |
|---|---|
| Forward P/E | 24.1x |
| P/S Ratio | 1.6x |
| P/B Ratio | 2.5x |
| P/TBV Ratio | 3.3x |
| P/OCF Ratio | 8.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 8.9x EBITDA.
| EV / Earnings | 14.2x |
|---|---|
| EV / Sales | 1.5x |
| EV / EBITDA | 8.9x |
Price Statistics
The stock is up 46.01% over 52 weeks and trades 26.09% below its 50-day average.
| Beta (1Y) | 0.99 |
|---|---|
| 52-Week Change | +46.01% |
| 1-Month Change | -30.07% |
| 3-Month Change | -24.76% |
| 6-Month Change | +4.85% |
| 5-Year Change | +104.71% |
| 10-Year Change | -72.74% |
| Total Return (1Y) | +46.01% |
| Total Return (3Y CAGR) | +22.85% |
| Total Return (5Y CAGR) | +16.21% |
| Return vs SPY (1Y) | +29.55% |
| Max Drawdown (1Y) | -36.59% |
| Max Drawdown (3Y) | -69.59% |
| Sharpe Ratio (1Y) | 0.63 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $9.66 |
| 200-Day Average | $8.04 |
| 52-Week Range | $4.79 to $11.50 |
| RSI (14 Days) | 24.1 |
| Average Volume (20 Days) | 485.33K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.03x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.03x |
|---|---|
| Quick Ratio | 2.81x |
| Debt / Equity | 0.00x |
| Interest Coverage | 5.79x |
Returns and Efficiency
Return on equity is 16.25% and return on assets is 11.75% over the last 12 months.
| Return on Equity (ROE) | 16.25% |
|---|---|
| Return on Assets (ROA) | 11.75% |
| ROA (5Y Average) | 5.02% |
| ROIC (5Y Average) | 17.16% |
| Asset Turnover | 1.14x |
| Inventory Turnover | 4.93x |
| Receivables Turnover | 6.93x |
| Cash Conversion Cycle | 102 days |
Taxes
Income tax took 15.19% of pretax income over the last 12 months.
| Income Tax (TTM) | $4.27M |
|---|---|
| Effective Tax Rate | 15.19% |
Scores
PBYI has an Altman Z-Score of -2.66, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.66 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $231.82M over the last 12 months is up 9.35% from the 12 months before.
| Revenue | $231.82M |
|---|---|
| Revenue Growth (YoY) | +9.35% |
| Gross Profit | $170.60M |
| Operating Income | $26.14M |
| Pretax Income | $28.10M |
| Net Income | $23.83M |
| EBITDA | $36.65M |
| Reported EPS (TTM) | $0.49 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.30% of the $202.77M in total assets.
| Cash and Equivalents | $41.55M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.55M |
| Net Cash Per Share | $0.81 |
| Working Capital | $105.66M |
| Shareholder Equity | $146.61M |
| Book Value Per Share | $2.84 |
| Tangible Book Value | $112.53M |
| Tangible Book Per Share | $2.18 |
| Total Assets | $202.77M |
| Total Liabilities | $56.15M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $46.04M |
|---|---|
| FCF Per Share | $0.89 |
| Depreciation and Amortization | $10.21M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 11.27%, against a 5-year average of 10.91%.
| Gross Margin | 73.59% |
|---|---|
| Operating Margin | 11.27% |
| Pretax Margin | 12.12% |
| Net Margin | 10.28% |
| EBITDA Margin | 15.81% |
| Gross Margin (5Y Average) | 74.13% |
| Operating Margin (5Y Average) | 10.91% |
| Net Margin (5Y Average) | 4.88% |
Growth
Revenue grew 0.05% a year over 3 years, and EPS 48.12% a year.
| Revenue Growth (3Y CAGR) | +0.05% |
|---|---|
| Revenue Growth (5Y CAGR) | +0.29% |
| EPS Growth (3Y CAGR) | +48.12% |
| FCF Growth (5Y CAGR) | +124.79% |
| Operating Income Growth (3Y CAGR) | +16.29% |
| Book Value Per Share Growth (2Y CAGR) | +50.80% |
Dividends and Yields
PBYI does not pay a dividend.
| Earnings Yield | 6.85% |
|---|---|
| Buyback Yield | -0.04% |
| Shareholder Yield | -0.04% |
Peer Position
Against 7 similar companies, PBYI has the lowest P/S.
P/S RatioPeer median 7.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +54.02%
| P/S Ratio | 1.6x vs 7.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +9.35% vs +54.02% median |
Analyst Forecast
Consensus estimates put EPS growth at -26.62% a year over the next 2 fiscal years.
| EPS Growth Forecast (2Y CAGR) | -26.62% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PBYI
What is PBYI's market cap?
Puma Biotechnology has a market cap of $379.47M. Its enterprise value, which adds debt and subtracts cash, is $337.92M.
What is PBYI's P/E ratio?
Puma Biotechnology has a trailing P/E ratio of 14.6x and a forward P/E of 24.1x.
How many shares of PBYI are outstanding?
Puma Biotechnology has 51.60M shares outstanding. The count is up 2.51% from a year earlier.
Does PBYI pay a dividend?
No. Puma Biotechnology does not pay a dividend.
How much debt does PBYI have?
Puma Biotechnology has $0 of total debt and $41.55M of cash and equivalents, a net cash position of $41.55M.
PBYI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors